CYTK

Cytokinetics, Incorporated

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$56.16

Price (1 Year)

$86.49 $53.69

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %25.9 / %30
Non-compliant assets / Total market cap %22.7 / %30
Non-compliant revenue / Total income %42.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Website

Analysis (Turkish): CYTK Hissesi Caiz mi, Helal mi? Cytokinetics, Incorporated Katılım Analizi